Filings & corporate actions
74 results filed
CSVNext results · Q2 FY27
Expected 2 Nov 2026 – 10 Nov 2026
Estimate: filed 33–41 days after quarter end, last 5 times
2026
- 10 AugresultsResults · Q1 FY27 · consolidated and standalone-2.7%NSE
- 20 JulshareholdingShareholding · 30 Jun 2026-3.3%NSE
- 28 MayshareholdingShareholding · 19 May 2026-4.2%NSE
- 18 MayresultsResults · Q4 FY26 · consolidated and standalone+10.8%NSE
- 16 AprshareholdingShareholding · 31 Mar 2026+1.1%NSE
- 9 FebresultsResults · Q3 FY26 · consolidated and standalone+1.8%NSE
- 19 JanshareholdingShareholding · 31 Dec 2025-2.4%NSE
Reaction to results · all yearsrose on day 0 in 27 of 74 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 10 Aug 2026 | -2.7% | -7.4% | -3.4% | 1.5× |
| Q4 FY26 | 18 May 2026 | +10.8% | +45.2% | +47.7% | 11.7× |
| Q3 FY26 | 9 Feb 2026 | +1.8% | -2.7% | -9.0% | 0.6× |
| Q2 FY26 | 10 Nov 2025 | -0.2% | -0.9% | +8.2% | 0.4× |
| Q1 FY26 | 4 Aug 2025 | -0.8% | -5.0% | -2.0% | 0.6× |
| Q4 FY25 | 20 May 2025 | +3.6% | +6.1% | -1.7% | 1.1× |
| Q3 FY25 | 10 Feb 2025 | -4.1% | -16.8% | -20.3% | 1.3× |
| Q2 FY25 | 4 Nov 2024 | +2.3% | +0.1% | +5.6% | 0.9× |
| Q1 FY25 | 5 Aug 2024 | -4.1% | -4.9% | -2.4% | 1.3× |
| Q4 FY24 | 24 May 2024 | -2.6% | -5.3% | +7.5% | 0.6× |
| Q3 FY24 | 5 Feb 2024 | +5.0% | +0.2% | +7.8% | 0.4× |
| Q2 FY24 | 6 Nov 2023 | -2.4% | +7.3% | +15.7% | 1.0× |
| Q1 FY24 | 7 Aug 2023 | -2.4% | -1.4% | +10.0% | 0.9× |
| Q4 FY23 | 22 May 2023 | +0.1% | -0.5% | +9.0% | 1.0× |
| Q3 FY23 | 13 Feb 2023 | -9.2% | -11.5% | -23.3% | 6.1× |
| Q2 FY23 | 7 Nov 2022 | -2.3% | -3.8% | -2.5% | 0.9× |
| Q1 FY23 | 8 Aug 2022 | -1.1% | +6.2% | +4.3% | 0.5× |
| Q4 FY22 | 17 May 2022 | -1.3% | -8.4% | -11.8% | 0.8× |
| Q3 FY22 | 4 Feb 2022 | -2.7% | -11.8% | -17.2% | 0.4× |
| Q2 FY22 | 2 Nov 2021 | -0.6% | -2.0% | -6.0% | 0.4× |
| Q1 FY22 | 27 Jul 2021 | -7.2% | +6.8% | +12.7% | 1.4× |
| Q4 FY21 | 18 May 2021 | +2.0% | +5.1% | +7.3% | 0.5× |
| Q3 FY21 | 9 Feb 2021 | -0.2% | -1.9% | -10.4% | 0.5× |
| Q2 FY21 | 10 Nov 2020 | +3.2% | +2.8% | +16.1% | 2.7× |
| Q1 FY21 | 5 Aug 2020 | -1.0% | -2.4% | -3.2% | 0.8× |
| Q4 FY20 | 3 Jun 2020 | +2.3% | +10.1% | +17.9% | 1.3× |
| Q3 FY20 | 1 Feb 2020 | -9.0% | +2.0% | -24.0% | 0.9× |
| Q2 FY20 | 5 Nov 2019 | +7.2% | +3.9% | +9.5% | 4.2× |
| Q1 FY20 | 30 Jul 2019 | -4.4% | -3.2% | -4.1% | 0.9× |
| Q4 FY19 | 9 May 2019 | -0.8% | -5.6% | -12.0% | 0.8× |
| Q3 FY19 | 11 Feb 2019 | +2.7% | +3.1% | +27.0% | 0.4× |
| Q2 FY19 | 9 Nov 2018 | +1.3% | -7.5% | -31.4% | 1.9× |
| Q1 FY19 | 8 Aug 2018 | +4.5% | +8.1% | +7.1% | 4.8× |
| Q4 FY18 | 21 Jun 2018 | -4.4% | -9.3% | -12.4% | 0.4× |
| Q3 FY18 | 2 Feb 2018 | -1.1% | +6.2% | -2.5% | 0.8× |
| Q2 FY18 | 31 Oct 2017 | -4.2% | -8.9% | +1.7% | 1.6× |
| Q1 FY18 | 8 Aug 2017 | -2.2% | +3.0% | +0.5% | 0.5× |
| Q4 FY17 | 27 May 2017 | -4.4% | +6.0% | +2.6% | 1.1× |
| Q3 FY17 | 31 Jan 2017 | -2.3% | +1.6% | +9.1% | 0.9× |
| Q2 FY17 | 7 Nov 2016 | -0.9% | -2.4% | +1.0% | 0.6× |
| Q1 FY17 | 3 Aug 2016 | +7.4% | +2.1% | +5.2% | 4.5× |
| Q4 FY16 | 10 May 2016 | -0.3% | +1.4% | -5.8% | 0.4× |
| Q3 FY16 | 4 Feb 2016 | -4.4% | -5.1% | +1.3% | 0.9× |
| Q2 FY16 | 5 Nov 2015 | -4.3% | -8.0% | -3.8% | 1.0× |
| Q1 FY16 | 3 Aug 2015 | 0.0% | -0.1% | -9.2% | 0.4× |
| Q4 FY15 | 6 May 2015 | -5.7% | -7.5% | -7.2% | 1.2× |
| Q3 FY15 | 31 Jan 2015 | +10.0% | +3.0% | +28.2% | 1.2× |
| Q2 FY15 | 5 Nov 2014 | +2.6% | +0.2% | +1.6% | 1.2× |
| Q1 FY15 | 18 Aug 2014 | +1.3% | +13.9% | +13.2% | 0.7× |
| Q4 FY14 | 5 May 2014 | +0.7% | +0.7% | +1.1% | 0.6× |
| Q3 FY14 | 3 Feb 2014 | +0.9% | -1.6% | -1.9% | 2.4× |
| Q2 FY14 | 6 Nov 2013 | +2.5% | +3.9% | +24.8% | 1.6× |
| Q1 FY14 | 1 Aug 2013 | -1.9% | -0.9% | -0.6% | 0.5× |
| Q4 FY13 | 22 May 2013 | -6.2% | +5.6% | -8.0% | 1.2× |
| Q3 FY13 | 24 Jan 2013 | +1.0% | +3.0% | +5.2% | 0.6× |
| Q2 FY13 | 29 Oct 2012 | -5.2% | -4.8% | +9.7% | 0.6× |
| Q1 FY13 | 1 Aug 2012 | -0.7% | +5.5% | -1.1% | 0.6× |
| Q4 FY12 | 2 May 2012 | -0.7% | -4.0% | +3.8% | 1.9× |
| Q3 FY12 | 1 Feb 2012 | -4.0% | -5.3% | -8.6% | 3.1× |
| Q2 FY12 | 24 Oct 2011 | -1.7% | -3.9% | -17.0% | 3.3× |
| Q1 FY12 | 8 Aug 2011 | -3.9% | -9.6% | -5.1% | 0.8× |
| Q3 FY11 | 1 Feb 2011 | +0.1% | -12.0% | -4.3% | 1.1× |
| Q2 FY11 | 21 Oct 2010 | +3.5% | +0.9% | +2.2% | 7.4× |
| Q1 FY11 | 26 Jul 2010 | 0.0% | +4.9% | +4.3% | 0.6× |
| Q3 FY10 | 23 Jan 2010 | -1.4% | -4.0% | +6.7% | 0.3× |
| Q2 FY10 | 24 Oct 2009 | -3.3% | -11.9% | -2.7% | 0.2× |
| Q1 FY10 | 20 Jul 2009 | +1.5% | -0.1% | +1.8% | 1.4× |
| Q3 FY09 | 24 Jan 2009 | +1.5% | +4.6% | +1.7% | 0.1× |
| Q2 FY09 | 27 Oct 2008 | -2.0% | +7.3% | -2.8% | 1.3× |
| Q1 FY09 | 29 Jul 2008 | -0.2% | +6.0% | +16.0% | 0.6× |
| Q4 FY08 | 14 May 2008 | +1.8% | -2.3% | -2.7% | 4.5× |
| Q3 FY08 | 24 Jan 2008 | -5.0% | -14.4% | -7.1% | 0.3× |
| Q2 FY08 | 27 Oct 2007 | +1.0% | +1.2% | +3.2% | 0.4× |
| Q1 FY08 | 23 Jul 2007 | -17.8% | -12.6% | -31.9% | — |
| Average | -0.9% | -0.6% | +0.5% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+314.1%
Profit YoY—
Interest cost YoY+145.9%
Revenue QoQ-97.8%
Profit QoQ-101.2%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +428.3% | — | — | — | — | — |
| Profit | — | — | — | — | — | — |
Key data
CSVOpen192.14
Day range191.40 – 197.69
52-week range108.00 – 289.00
From 52w high-31.9%
RSI (14)47.6
ATR (14)8.77
Volume6.89L
Avg volume (20D)9.98L
Rel volume0.69×
Volatility (1Y)56.2%
Turnover₹13.6Cr
SMA 50 / 200201.28 / 173.54
Delivery percentage
Latest · 6 Oct 202646.4%
20-day avg42.1%
1-year avg38.6%
Percentile (own history)76th
Range4.0–100.0%
Sessions1,731
Over the last 20 sessions SPARC settled 42.1% of its traded quantity, which is ordinary for an NSE equity. Its one-year average is 38.6%, so recent sessions are running 3.5 points higher than usual. The latest session ranks higher than 76% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +2.94% | -2.94% | -2.79% | -26.08% | +58.71% | +49.43% |
Valuation
CSVMarket cap₹6,389 Cr
P/E (TTM)4.0
EPS (TTM)48.82
Shares outstanding32.45Cr
Listed18 Jul 2007
Ownership
CSVPromoter—
Promoter Δ QoQ—
Public—
FII—
DII—
Pledged—
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 7.9 | 8.5 | 1,853.2 | 39.9 |
| YoY chg | -38.9% | -43.3% | +6715.8% | +314.1% |
| Net profit (₹ Cr) | (75.9) | (80.4) | 1,761.3 | (20.8) |
| YoY chg | — | — | — | — |
| Net margin | -965.0% | -951.7% | 95.0% | -52.1% |
| EPS | -2.34 | -2.48 | 0.00 | -0.64 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 65.67% · public 34.33%2021-092026-06
- Promoter
- Public and others
- Promoter
- 65.67%
- Public
- 34.33%
- Promoter change
- 0.00 pp
- Filed
- 20 Jul 2026
- FII
- 3.90%
- DII
- 0.09%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 21.2 | 13.9 | 16.6 | 16.8 | 12.9 | 14.9 | 27.2 | 9.6 | 7.9 | 8.5 | 1,853.2 | 39.9 | |
| Other income | 8.5 | 6.4 | 4.4 | 1.6 | 0.0 | 0.2 | 0.0 | 9.1 | 0.0 | 0.0 | 1.8 | 23.7 | |
| Total income | 29.7 | 20.3 | 21.0 | 18.4 | 12.9 | 15.1 | 27.2 | 18.8 | 7.9 | 8.5 | 1,855.0 | 63.6 | |
| Total expenses | 116.1 | 119.9 | 126.4 | 113.9 | 120.1 | 94.5 | 87.9 | 70.6 | 83.7 | 76.4 | 94.1 | 84.3 | |
| └ Finance costs | 0.3 | 0.3 | 0.9 | 0.6 | 1.1 | 2.8 | 4.5 | 6.2 | 7.5 | 8.8 | 11.6 | 8.1 | |
| └ Depreciation | 3.2 | 3.2 | 3.1 | 3.1 | 3.2 | 3.1 | 3.0 | 2.7 | 2.6 | 2.6 | 2.4 | 2.2 | |
| Profit before tax | (86.4) | (99.7) | (105.4) | (95.5) | (107.2) | (79.4) | (60.7) | (51.8) | (75.8) | (80.4) | 1,761.0 | (20.7) | |
| Tax expense | 0.0 | 0.0 | 0.4 | 0.4 | 0.2 | 0.1 | (0.9) | 0.1 | 0.1 | 0.1 | (0.4) | 0.1 | |
| Net profit | (86.4) | (99.7) | (105.8) | (95.9) | (107.3) | (79.5) | (59.8) | (51.9) | (75.9) | (80.4) | 1,761.3 | (20.8) | |
| EPS | -2.66 | -3.07 | -3.26 | -2.96 | -3.31 | -2.45 | -1.84 | -1.60 | -2.34 | -2.48 | 54.27 | -0.64 | |
| Net margin | -408.03% | -718.98% | -638.83% | -570.49% | -834.60% | -533.27% | -219.82% | -538.07% | -965.01% | -951.72% | 95.04% | -52.05% | |
| PBT margin | -408.03% | -718.98% | -636.53% | -568.11% | -833.36% | -532.80% | -223.13% | -537.45% | -964.25% | -950.89% | 95.02% | -51.78% | |
| Tax rate | — | — | — | — | — | — | — | — | — | — | -0.02% | — |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 10 Aug 2026.
SPARC at a glance
- SPARC closed at ₹196.89 on 6 Oct 2026, +2.94% on the day, +49.4% over one year, 31.9% below its 52-week high of ₹289.
- Delivery was 46.4% of traded quantity on 6 Oct 2026, the 76th percentile of its own 1,731 sessions with a reading (20-session average 42.1%, 1-year average 38.6%).
- Market capitalisation is ₹6,389 crore at a trailing P/E of 4.0 (trailing EPS ₹48.82).
- Q1 FY27 results (consolidated, filed 10 Aug 2026): revenue ₹40 crore (+314.1% year on year), net profit ₹-21 crore; the price moved -2.7% on the first session after.
- Promoters held 65.67% at 30 Jun 2026, unchanged on the previous filing.
- Q2 FY27 results are expected between 2 Nov 2026 and 10 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE232I01014
SeriesEQ
Listed18 Jul 2007
History from18 Jul 2007
Sessions4,758
Turnover rank#775
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE